Hepatocellular Carcinoma and Immunotherapy
Can anti-PD1/PD-L1 Immunotherapy Promote Macrophage Activity against HCC cells?
DOI:
https://doi.org/10.47611/jsrhs.v12i3.4714Keywords:
Hepatocelular carcinoma, PD1/PD-L1 antibodies, Macrophages, MHCI/MHCII, Immunosuppression, Anti-tumor activityAbstract
With over 750,000 new cases identified annually, hepatocellular carcinoma (HCC) continues to be a threat, with current immunotherapies producing ineffective results in a majority of patients. PD1/PD-L1 antibodies have risen as another treatment option, but previous studies have only analyzed these antibodies in the tumor microenvironment. In order to understand how exactly these PD1/PD-L1 blockers affect macrophages and their anti-tumor macrophages, this study isolated the macrophage cells and tumor cells. Two protocols were followed, one with the B16F10 melanoma cell line, in order to determine proper procedures and determine a point of comparison, and one with the R1LWT liver cancer cell line. In the end, the B16F10 cell line responded positively to the PD1/PD-L1 antibodies, with increased MHCI/MHCII activation. On the other hand, the R1LWT cell line reacted oppositely, opening new inquiries into other pathways by which immunosuppression occurs.
Downloads
References or Bibliography
A, T. (n.d.). Immunology: What cells have a myeloid lineage and how are they identified? Blog.cellsignal.com. https://blog.cellsignal.com/immunology-what-cells-have-a-myeloid-lineage-and-how-are-they-identified
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017). PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology, 8. https://doi.org/10.3389/fphar.2017.00561
Bocanegra, A., Blanco, E., Fernandez-Hinojal, G., Arasanz, H., Chocarro, L., Zuazo, M., Morente, P., Vera, R., Escors, D., & Kochan, G. (2020). PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. International Journal of Molecular Sciences, 21(16), 5918. https://doi.org/10.3390/ijms21165918
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013). The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages. BioMed Research International, 2013, 1–15. https://doi.org/10.1155/2013/187204
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., Manos, M. P., Font-Tello, A., Gjini, E., Lako, A., Lim, K., Conway, J., Tewari, A. K., Zeng, Z., Sahu, A. D., & Tokheim, C. (2021). Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 11(6), 1524–1541. https://doi.org/10.1158/2159-8290.cd-20-0812
Hirayama, D., Lida, T., & Nakase, H. (2017). The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. International Journal of Molecular Sciences, 19(1), 92. https://doi.org/10.3390/ijms19010092
Hu, Z., Ye, L., Xing, Y., Hu, J., & Xi, T. (2018). Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-017-18641-y
Huang, Y., Ge, W., Zhou, J., Gao, B., Qian, X., & Wang, W. (2021). The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. Journal of Cancer, 12(5), 1284–1294. https://doi.org/10.7150/jca.51346
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., Korangy, F., & Greten, T. F. (2013). Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. Journal of Hepatology, 59(5), 1007–1013. https://doi.org/10.1016/j.jhep.2013.06.010
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2021). Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Therapy. https://doi.org/10.1038/s41417-021-00303-x
Kuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009). Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of Experimental Medicine, 206(6), 1327–1337. https://doi.org/10.1084/jem.20082173
López-Requena, A., Burrone, O. R., & Cesco-Gaspere, M. (2012). Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Frontiers in Oncology, 2. https://doi.org/10.3389/fonc.2012.00159
Macek Jilkova, Z., Kurma, K., & Decaens, T. (2019). Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment. Cancers, 11(10), 1487. https://doi.org/10.3390/cancers11101487
National Cancer Institute. (2011, February 2). https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adaptive-immunity. Www.cancer.gov. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adaptive-immunity
Ovchinnikov, A. G., Arefieva, T. I., Potekhina, A. V., Filatova, A. Yu., Ageev, F. T., & Boytsov, S. А. (2020). The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction. Acta Naturae, 12(2), 40–51. https://doi.org/10.32607/actanaturae.10990
Pu, Y., & Ji, Q. (2022). Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.874589
Rock, K. L., Reits, E., & Neefjes, J. (2016). Present Yourself! By MHC Class I and MHC Class II Molecules. Trends in Immunology, 37(11), 724–737. https://doi.org/10.1016/j.it.2016.08.010
Romano, E., Rufo, N., Korf, H., Mathieu, C., Garg, A. D., & Agostinis, P. (2018). BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells. Oncotarget, 9(25). https://doi.org/10.18632/oncotarget.24815
Stout, R. D., Jiang, C., Matta, B., Tietzel, I., Watkins, S. K., & Suttles, J. (2005). Macrophages Sequentially Change Their Functional Phenotype in Response to Changes in Microenvironmental Influences. The Journal of Immunology, 175(1), 342–349. https://doi.org/10.4049/jimmunol.175.1.342
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020). Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Frontiers in Oncology, 10, 554313. https://doi.org/10.3389/fonc.2020.554313
Sun, J.-Y., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X.-J., & Ji, J. (2020). Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Research, 8(1). https://doi.org/10.1186/s40364-020-00212-5
Tian, Z., Hou, X., Liu, W., Han, Z., & Wei, L. (2019). Macrophages and hepatocellular carcinoma. Cell & Bioscience, 9(1). https://doi.org/10.1186/s13578-019-0342-7
Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017). Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Frontiers in Immunology, 8. https://doi.org/10.3389/fimmu.2017.00292
Xu, W., Cheng, Y., Guo, Y., Yao, W., & Qian, H. (2022). Targeting tumor associated macrophages in hepatocellular carcinoma. Biochemical Pharmacology, 199, 114990. https://doi.org/10.1016/j.bcp.2022.114990
Yoo, S. Y., Badrinath, N., Woo, H. Y., & Heo, J. (2017). Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators of Inflammation, 2017(5198798), 1–12. https://doi.org/10.1155/2017/5198798
Zeng, Z., Yang, B., & Liao, Z. (2020). Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review). Oncology Letters. https://doi.org/10.3892/ol.2020.11909
Zhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W., Yao, Y., Chen, Y., & Jiang, R. (2020). IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer, 8(1), e000285. https://doi.org/10.1136/jitc-2019-000285
Published
How to Cite
Issue
Section
Copyright (c) 2023 Manasi Vegesna; Dr. Jessica Lancaster, Dr. Ildefonso Alves da Silva
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
